Core Viewpoint - Crown Castle Inc. (NYSE:CCI) is currently trading near its 52-week lows, but analysts maintain a bullish outlook with a 12-month price target indicating over 24% upside potential from current levels [1] Group 1: Analyst Ratings and Price Targets - Brandon Nispel from KeyBanc reiterated a Buy rating on Crown Castle with a price target of $115 [2] - Batya Levi from UBS also maintained a Buy rating but adjusted the price target from $127 to $116 [2] - Levi sees a favorable risk/reward profile for tower stocks in 2026, supporting her Buy rating [3] Group 2: Impact of DISH Wireless Default - Nispel reduced the price target from $120 to $115 due to DISH Wireless defaulting on payment applications, which led to the removal of leasing from forecasts [3] - This default is expected to result in a $12 million omission from 2026 leasing forecasts and add $200 million of churn in 2027 estimates [4] Group 3: Company Overview - Crown Castle Inc. owns and operates over 40,000 cell towers and 90,000 route miles of fiber across major U.S. markets [5] - The company leases space and capacity on its communications infrastructure through long-term contracts with wireless carriers and network providers [5]

Core Viewpoint - Humana Inc. (NYSE:HUM) is considered a strong investment opportunity despite recent challenges, with Wall Street showing optimism ahead of its upcoming earnings report [1][4]. Group 1: Earnings Expectations - Humana Inc. is expected to report quarterly revenue of approximately $32.08 billion for fiscal Q4 2025, with a negative GAAP EPS of $4.08 [1]. - Analysts have varying ratings, with Truist Financial maintaining a Hold rating and Bernstein issuing a Buy rating with a price target of $344 [2]. Group 2: Market Impact and Challenges - The Medicare Advantage Advance Notice is anticipated to significantly affect healthcare stocks, including Humana, as it sets benchmarks for insurers [3]. - Recent proposals from the Trump administration for a smaller-than-expected increase in Medicare Advantage rates have led to a decline in Humana's share price by over 24%, nearing its 52-week lows [4]. Group 3: Company Overview - Humana Inc. is a leading health insurance and well-being company, focusing on Medicare Advantage plans, Medicaid services, and specialty insurance products for individuals and employer groups [4].

Group 1 - Cenovus Energy Inc. is considering divesting its conventional oil and gas assets in Alberta to reduce debt after its C$8.5 billion acquisition of MEG Energy [3][4] - The potential sale of these assets is expected to generate approximately C$3 billion ($2.17 billion) [3] - The company aims to strengthen its balance sheet, targeting a reduction of net debt from around C$10.7 billion to C$4 billion over time [4] Group 2 - Cenovus Energy's share price increased by 7.47% from January 22 to January 29, 2026, making it one of the top-performing energy stocks during that week [1] - The company plans to invest C$3.6 billion in its oil sands business in 2026, an increase from C$2.8 billion in the previous budget [4] - Cenovus Energy was recently listed among the 10 Best Natural Gas Stocks to Buy [5]

Core Viewpoint - Frontline plc (NYSE:FRO) experienced a significant share price increase of 11.85% from January 22 to January 29, 2026, making it one of the top-performing energy stocks during that week [1]. Company Developments - Frontline plc is a global shipping company specializing in the ownership and operation of oil and product tankers [2]. - On January 26, 2026, Frontline announced the signing of 1-year time charter-out agreements for seven of its Very Large Crude Carriers (VLCCs), starting from late January to April 2026, at a daily rate of $76,900 per vessel. The counterparty for this deal is reportedly South Korea's Sinokor Maritime [3]. - CEO Lars H. Barstad highlighted that the current charter rates are unprecedented and not seen for decades, indicating that Frontline remains largely exposed to spot market fluctuations after these contracts take effect, which positions the company to benefit from a volatile market [3]. Market Analysis - Analyst Kristoffer Barth Skeie from Arctic Securities noted that the charter rate is 7% above recent broker quotes, marking a new high in the time-charter market. This development has significantly reduced Frontline's risk exposure, with time-charter coverage for the VLCC fleet projected to increase to 8% in Q1 2026, 24% in Q2 and Q3, 23% in Q4, and 15% in Q1 2027, compared to only one vessel on long-term charter prior to these agreements [4]. Performance Overview - Over the past year, Frontline plc's share price has surged by more than 63%, indicating strong performance in the market [5].

DraftKings Inc. (NASDAQ:DKNG) is one of the stocks that Jim Cramer shared takes on, along with navigating market shortages. When a caller inquired about the stock, Cramer remarked: Okay, I like DraftKings, but I’ve decided, you know what, without Florida, without Texas, without California gambling, it’s just going to be like, I don’t know, it’s in the wilderness. I don’t know. I want it out of the wilderness. It’s not an expensive stock. Or maybe we need a lot of consolidation. That could do it. A tech ...

Core Viewpoint - AbbVie Inc. is recognized as one of the 12 best long-term stocks to buy, despite facing some challenges in clinical trials [1]. Group 1: Market Analysis - Citi has adjusted its price target for AbbVie to $230 from $235 while maintaining a Neutral rating, indicating a more supportive backdrop for the biopharma sector in 2026 due to manageable earnings expectations and reduced policy-related risks [2]. - The overall sentiment in the biopharma space suggests that earnings may exceed previous fears, contributing to a more favorable investment environment [2]. Group 2: Clinical Developments - AbbVie and Genmab's blood cancer drug, epcoritamab, did not demonstrate a statistically significant survival benefit in a late-stage study involving 483 patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - Despite the lack of clear survival benefits, the study revealed positive outcomes, such as a higher number of patients achieving undetectable cancer levels, longer response durations, and improved time before requiring further treatment [4]. - Epcoritamab is already approved in several countries for other lymphoma indications, marketed as Epkinly in the U.S. and Japan, and as Tepkinly in the European Union [5].

GoldMining Inc. (NYSE:GLDG) is among the 11 Best Gold Stocks to Buy for 2026. Roth Capital is Bullish on GoldMining Inc. (GLDG) On January 7, 2026, TheFly reported that Roth Capital reaffirmed its Buy recommendation. It lifted GoldMining Inc. (NYSE:GLDG)’s price objective to $2.80 from $2.60. The increase is a result of further drilling at the Sao Jorge project, which the company claims has potential for resource growth, as well as a better valuation of the company’s interests. GoldMining Inc. (NYSE:GL ...

Vista Gold Corp. (NYSE:VGZ) is among the 11 Best Gold Stocks to Buy for 2026. Vista Gold Corp. (VGZ) Establishes a Goal to Begin Thorough Engineering and Design at Mt. Todd Vista Gold Corp. (NYSE:VGZ) stated that it plans to start thorough engineering and design at its Mt Todd gold project by early 2027, based on a January 13, 2026, report by TheFly. The Mt Todd Feasibility Study, completed in July 2025, proposed a smaller initial project by targeting higher-grade ore, lowering initial capital expenditur ...

New Found Gold Corp. (NYSE:NFGC) is among the 11 Best Gold Stocks to Buy for 2026. New Found Gold Corp. (NFGC) Completes Key Milestone at Queensway Gold Project by Entering into Phase 1 EPCM Contract On January 26, 2026, New Found Gold Corp. (NYSE:NFGC) entered into a Phase 1 EPCM contract with WSP Canada Inc. for site planning and detailed engineering of an offsite milling plant, advancing its 100%-owned Queensway Gold Project in Newfoundland and Labrador. The corporation intends to grow and modernize i ...

Caledonia Mining Corporation Plc (NYSE:CMCL)  is among the 11 Best Gold Stocks to Buy for 2026. Caledonia Mining Corporation Plc (CMCL) Raises $150 Million for Zimbabwe's Gold Mine in a Rare International Capital Raise Caledonia Mining Corporation Plc (NYSE:CMCL) reportedly obtained $150 million through a seven-year convertible bond sale to finance the construction of its Bilboes project, which is anticipated to grow into Zimbabwe’s largest gold mine, based on a January 21, 2026, Reuters story. After yea ...